Zürich Switzerland 2nd of June 2020 – HypoPet AG today announced the ASF-INNOVAC consortium in which it is the lead SME was ranked 1st among 378 funding applications and will thus receive funding for 3 years to research and develop a vaccine against the African Swine Fever; one of the most serious infectious diseases affecting commercial livestock worldwide.
Zürich Switzerland 17th of April 2019 – HypoPet AG today announced the publication of important preclinical data for their cat allergy vaccine, HypoCatTM.
The data were published online 17th of April 2019 in an article entitled “Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. “in the Journal of Allergy and Clinical Immunology.
Download media release here
Zürich Switzerland 19th of March 2019 – HypoPet AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals. The data were published online 12th of March 2019 in an article entitled “Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis” in the Annals of the Rheumatic Diseases.
Download media release here
9th January 2019 - HypoPet to present at Animal Health Investment Forum London
HypoPet AG today announced that it has been selected as a finalist to present at the prestigious Animal Health Investment Europe Forum in February 2019. The Animal Health Innovation showcase provides an opportunity for the most exciting and innovative emerging animal health companies, selected by committee, to present their breakthrough innovations and business to investors and industry professionals.
Company founder and CSO Martin Bachmann will give HypoPet’s 10 min presentation in London, Aldersgate on the 26th of February.
Press Releases 2018
Proof of concept data for HypoPet’s virus-like particle vaccine for treating canine atopic dermatitis published in leading allergy journal
Zürich Switzerland 11th of April 2018 – HypoPet AG today announced the publication of Proof of Concept data for a vaccine for treating canine atopic dermatitis (CAD) in the renowned Journal of Allergy and Clinical Immunology. The data were published online 4th of April 2018 in an article entitled “Vaccination against IL-31 for the treatment of atopic dermatitis in dogs”.
Press releases 2017
HypoPet AG merges with Saiba Animal Health GmbH
In May 2017 HypoPet AG announced a merger with Saiba Animal Health GmbH. Saiba Animal Health's CAD vaccine (partnered with Benchmark Holdings PLC) and product pipeline of novel vaccine candidates subsequently became part of HyopPet's product candidate pipeline .
Press release 2015
Licensing Deal for Canine Atopic Disease vaccine
Benchmark secures licensing deal for Canine Atopic Diseases vaccine.
Press Releases 2014
Agreement for HypoCat
Benchmark Holdings PLC announces an agreement with HypoPet AG for HypoCat
2013 Press Releases
Article of the newspaper Neue Luzerner Zeitung
Press release of the University of Zürich
Hypopet release of winning Swiss Technology Award
Keep your Cat at Home
Article of the newspaper Thurgauer Zeitung / St. Galler Tagblatt
Article of the newspaper Neue Zürcher Zeitung